Should the sex of the fetus be considered when administering antenatal corticosteroids to preterm fetuses?
Journal of Obstetrics and Gynaecology Research · 2024
DOI: 10.1111/jog.16062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2024. Verfasst von Erdal Şeker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Osmaniye State Hospital, Osmaniye, Turkey. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Aim
We aimed to determine whether the effect of antenatal corticosteroids (ANS) differs in male and female fetuses without anomalies born before 32 weeks in terms of mortality and short‐term morbidity.
Methods
This single‐center retrospective study included infants born before 32 weeks' gestation and admitted to the neonatal intensive care unit between January 1, 2018, and December 31, 2020.
Results
The study included 210 infants with a median gestational age of 28.6 weeks (24–31.6), a birth weight of 1065 g (445–2165), and an ANS use rate of 80%. Compared to female fetuses exposed to ANS, male fetuses exposed to ANS had a lower mortality rate (23% and 11%, respectively, p = 0.038), but there were no differences in intraventricular hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, respiratory distress syndrome, and APGAR scores of 1st and 5th but an increased rate of bronchopulmonary dysplasia (moderate/severe) ( p = 0.008). In addition, the mortality rate was similar in exposed and unexposed female fetuses ( p = 0.850). Enzyme activities and steroid levels in the placenta might be different in male and female fetuses, which could explain the results of ANS administration.
Conclusions
In our study, we have shown that ANS has no effect on mortality in female fetuses younger than 32 weeks. Future studies may focus on adjusting the administration of ANS based on fetal sex, altering the dose or taking fetal sex into account when performing ANS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Osmaniye State Hospital, Osmaniye, Turkey.
- Department of Neonatology, Ankara University School of Medicine, Ankara, Turkey.
- Department of Obstetrics and Gynecology, Ankara University School of Medicine, Ankara, Turkey.
- Department of Obstetrics and Gynecology, Gazi Yasargil Education and Training Hospital, Diyarbakir, Turkey.
ORCID-Profile: Erdal Şeker, Mehmet Obut
Zitieren
APA
Şeker, E., Kraja, E., Çakır, M. S., Köstekçi, Y. E., Obut, M., Okulu, E., Erdeve, Ö., Atasay, F. B., Arsan, S., & Koç, A. (2024). Should the sex of the fetus be considered when administering antenatal corticosteroids to preterm fetuses?. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16062
Vancouver
Şeker E, Kraja E, Çakır MS, Köstekçi YE, Obut M, Okulu E, et al. Should the sex of the fetus be considered when administering antenatal corticosteroids to preterm fetuses?. Journal of Obstetrics and Gynaecology Research. 2024. doi:10.1111/jog.16062
BibTeX
@article{eker2024,
author = {Şeker, Erdal and Kraja, Elvis and Çakır, Maide Selin and Köstekçi, Yasemin Ezgi and Obut, Mehmet and Okulu, Emel and Erdeve, Ömer and Atasay, Fatma Begüm and Arsan, Saadet and Koç, Acar},
title = {Should the sex of the fetus be considered when administering antenatal corticosteroids to preterm fetuses?},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2024},
doi = {10.1111/jog.16062}
}
EUVIMED